LeMaitre Vascular (LMAT) Set to Announce Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) will be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect LeMaitre Vascular to post earnings of $0.39 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The firm had revenue of $48.90 million for the quarter, compared to analysts’ expectations of $49.01 million. During the same quarter last year, the business posted $0.25 earnings per share. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Trading Down 1.3 %

Shares of NASDAQ:LMAT traded down $0.86 during midday trading on Tuesday, reaching $65.38. 4,768 shares of the company were exchanged, compared to its average volume of 110,884. The stock has a market cap of $1.47 billion, a PE ratio of 49.09, a price-to-earnings-growth ratio of 2.82 and a beta of 0.87. The business’s fifty day moving average is $65.43 and its two-hundred day moving average is $58.29. LeMaitre Vascular has a one year low of $44.27 and a one year high of $74.64.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Thursday, March 14th were given a $0.16 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend was Wednesday, March 13th. LeMaitre Vascular’s payout ratio is currently 47.76%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total transaction of $517,500.00. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $157,182. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $157,182. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 27,859 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.73, for a total value of $1,942,608.07. Following the sale, the chief executive officer now owns 2,255,737 shares in the company, valued at approximately $157,292,541.01. The disclosure for this sale can be found here. In the last three months, insiders sold 114,036 shares of company stock valued at $7,873,749. Corporate insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LMAT. Barrington Research raised their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. KeyCorp began coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their target price for the company from $59.00 to $75.00 in a research note on Friday. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $69.33.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.